A U.S. group that reviews the value of medicines issued a critical report on Novartis's new multiple sclerosis drug Mayzent, calling its $88,561 list price "far out of line" compared with its benefits for patients.
from Reuters: U.S. https://reut.rs/2XrWvrS
0 comments:
Post a Comment